Arginine Deiminase (ADI), Pseudomonas Aeruginosa Recombinant | P1411

Arginine deiminase (ADI) is a potential anti-tumor biologics for the treatment of arginine-auxotrophic tumors, such as hepatocellular carcinomas and melanomas. ADI hydrolyzes arginine to citrulline and ammonia.

P1411 | Arginine Deiminase (ADI), Pseudomonas Aeruginosa Recombinant DataSheet

Biomolecule/Target :

Synonyms: Arginine dihydrolase, AD, arcA

Alternates names: Arginine dihydrolase, AD, arcA

Taglines: A potential anti-tumor biologics

NCBI Gene ID #: 881801

NCBI Gene Symbol: arcA

Gene Source: Pseudomonas Aeruginosa

Accession #: P13981

Recombinant: True

Source: E.coli

Purity by SDS-PAGE: >95%

Assay: SDS-PAGE.

Purity:

Assay #2:

Endotoxin Level:

Activity (Specifications/test method): This enzyme has a specific activity of ≥ 100 mU/mg based on its conversion of arginine to citrulline, which can be detected fluorometrically at Ex/Em=535/595 using ’s Methionine Assay Kit (Cat. No. K442).

Biological activity:

Results: 100 mU/mg

Binding Capacity:

Unit Definition: One unit is defined as the amount of enzyme that will hydrolyze 1.0 umole of arginine to citrulline per minute at pH 7.4 and 25 ÌŠC.

Molecular Weight: 46.3 kDa with N-terminal 6X-His tag

Concentration:

Appearance: Sterile Filtered colorless solution

Physical form description: Liquid

Reconstitution Instructions:

Amino acid sequence: aa 1-418

Handling: Centrifuge the vial prior to opening.

Usage: